Who Paid My Doc
Garry Gold
Diagnostic Radiology Stanford, CA Medical Doctor
NPI 1043303357 CMS profile 1484
300 Pasteur Dr, Stanford, CA 94305
General payments
$528,031
Research payments
$0
Ownership & investment interest
$757,455
Research they led as principal investigator
$4,725,159
Through program year 2025, Garry Gold of Stanford, CA is reported in the CMS Open Payments database as having received $528,031 across 73 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $4,725,159 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $757,455 across 2 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $13,258 | 14 | |
| 2024 | General | $2,644 | 2 | |
| 2023 | General | $13,822 | 20 | |
| 2022 | General | $12,284 | 8 | |
| 2021 | General | $231,556 | 7 | |
| 2020 | General | $8,267 | 5 | |
| 2019 | General | $246,199 | 17 | |
| 2025 | Ownership | $757,455 | 2 |
Beside peers
- Garry Gold
- Diagnostic Radiology median
- Middle half of Diagnostic Radiology
- National median
In program year 2025, general payments to Garry Gold were reported at $13,258. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.
Show as a table
| Year | Garry Gold | Diagnostic Radiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $246,199 | $108 | $29–$318 | $163 |
| 2020 | $8,267 | $65 | $21–$252 | $114 |
| 2021 | $231,556 | $92 | $24–$292 | $132 |
| 2022 | $12,284 | $104 | $29–$294 | $149 |
| 2023 | $13,822 | $110 | $29–$337 | $160 |
| 2024 | $2,644 | $113 | $30–$356 | $164 |
| 2025 | $13,258 | $112 | $32–$349 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
73 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Diagnostic Radiology in California
Murray Reicher
Diagnostic Radiology · San Diego, CA
Agnes Santosa
Diagnostic Radiology · San Diego, CA
Robert Suh
Diagnostic Radiology · Los Angeles, CA
Jonathan Chung
Diagnostic Radiology · San Diego, CA
Gary Ulaner
Diagnostic Radiology · Los Angeles, CA
Michael Trambert
Diagnostic Radiology · Santa Barbara, CA
Related records
Diagnostic Radiology in California
Practitioners in the same specialty and state, ranked by reported value.
All Diagnostic Radiology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.